Enhancing cancer chemo-immunotherapy by biomimetic nanogel with tumor targeting capacity and rapid drug-releasing in tumor microenvironment.
10.1016/j.apsb.2021.11.004
- Author:
Lihuan SHANG
1
;
Xue JIANG
1
;
Ting YANG
1
;
Hongbo XU
1
;
Qi XIE
1
;
Mei HU
1
;
Conglian YANG
1
;
Li KONG
1
;
Zhiping ZHANG
1
Author Information
1. Tongji School of Pharmacy, Huazhong University of Science and Technology, Wuhan 430030, China.
- Publication Type:Journal Article
- Keywords:
Biomimetic modification;
Cancer cell membrane;
Chemo-immunotherapy;
Interleukin-2;
Nanogel;
Paclitaxel;
Rapid release;
pH-responsive
- From:
Acta Pharmaceutica Sinica B
2022;12(5):2550-2567
- CountryChina
- Language:English
-
Abstract:
In the development of chemo-immunotherapy, many efforts have been focusing on designing suitable carriers to realize the co-delivery of chemotherapeutic and immunotherapeutic with different physicochemical properties and mechanisms of action. Besides, rapid drug release at the tumor site with minimal drug degradation is also essential to facilitate the antitumor effect in a short time. Here, we reported a cancer cell membrane-coated pH-responsive nanogel (NG@M) to co-deliver chemotherapeutic paclitaxel (PTX) and immunotherapeutic agent interleukin-2 (IL-2) under mild conditions for combinational treatment of triple-negative breast cancer. In the designed nanogels, the synthetic copolymer PDEA-co-HP-β-cyclodextrin-co-Pluronic F127 and charge reversible polymer dimethylmaleic anhydride-modified polyethyleneimine endowed nanogels with excellent drug-loading capacity and rapid responsive drug-releasing behavior under acidic tumor microenvironment. Benefited from tumor homologous targeting capacity, NG@M exhibited 4.59-fold higher accumulation at the homologous tumor site than heterologous cancer cell membrane-coated NG. Rapidly released PTX and IL-2 enhanced the maturation of dendritic cells and quickly activated the antitumor immune response in situ, followed by prompted infiltration of immune effector cells. By the combined chemo-immunotherapy, enhanced antitumor effect and efficient pulmonary metastasis inhibition were achieved with a prolonged median survival rate (39 days).
